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Abstract  
The postoperative low cardiac output is one of the most important complications following cardiac 
surgery and is associated with increased morbidity and mortality. The condition requires inotropic 
support to achieve adequate hemodynamic status and tissue perfusion. While catecholamines are 
utilised as a standard therapy in cardiac surgery, their use is limited due to increased oxygen 
consumption. Levosimendan is calcium sensitising inodilatator expressing positive inotropic effect 
by binding with cardiac troponin C without increasing oxygen demand. Furthermore, the drug opens 
potassium ATP (KATP) channels in cardiac mitochondria and in the vascular muscle cells, showing 
cardioprotective and vasodilator properties, respectively. In the past decade, levosimendan 
demonstrated promising results in treating patients with reduced left ventricular function when 
administered in peri- or post- operative settings. In addition, pre-operative use of levosimendan in 
patients with severely reduced left ventricular ejection fraction may reduce the requirements for 
postoperative inotropic support, mechanical support, duration of intensive care unit stay as well as 
hospital stay and a decrease in post-operative mortality. However, larger studies are needed to 
clarify clinical advantages of levosimendan versus conventional inotropes. 
 
 
 
 
 
 
Introduction 
 
Patients undergoing open heart surgery with 
cardiopulmonary bypass (CPB) experience global 
perioperative heart ischemia followed by reperfusion. 
This leads to different degrees of myocardial 
dysfunction due to free radical formation, impairment 
of the coronary vasculature and calcium overload [1, 
2]. If severe enough this can cause postoperative low 
cardiac output syndrome (LCOS), a life-threatening 
complication with a prevalence of about 10% and a 
mortality of 17% [3]. 
Acute worsening of the left heart failure is 
commonly treated pharmacologically with intravenous 
positive inotropic agents, or mechanical support in 
severe cases [4]. Currently, beta-adrenergic agonists 
and phosphodiesterase inhibitors are most frequently 
used in clinical practice [4, 5]. Beta-adrenergic agents 
increase cardiac output (CO), cardiac index (CI) and 
stroke volume index by increasing intracellular cyclic 
adenosine monophosphate (cAMP) production and 
calcium influx to myocytes [6]. Phosphodiesterase 
inhibitors, like milrinone, do the same by inhibiting 
cAMP degradation [7]. This results in increased 
cellular energy demands and oxygen consumption, 
can trigger arrhythmias and can even be cardiotoxic 
[8, 9]. 
Levosimendan is a newer inotropic agent 
belonging to a class of calcium sensitizers that 
 Bozhinovska et al. Levosimendan in Decreased Left Ventricular Function Undergoing Cardiac Surgery 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2016 Sep 15; 4(3):510-516.                                                                                                                                                         511 
 
increase myocardial contractility by increasing the 
sensitivity of troponin C for calcium without increasing 
myocardial oxygen consumption [10]. Unlike some 
calcium sensitizers, levosimendan increases 
myocardial contractility without impairing diastolic 
cardiac function [11]. It displays vasodilator properties 
as well [12]. 
This review is focused on the impact of 
levosimendan in patients with left heart failure 
undergoing open heart surgery. Pharmacologic 
features of this drug will be briefly presented as well. 
 
 
Used Literature 
 
The data sources used in this article are 
PubMed, Excerpta Medica, Reference Update, 
BIOSIS, Science Citation Index and Index Medicus. 
The abstract and papers were found by searching 
([levosimendan ] and [surgery OR bypass OR valve 
OR CABG ]) were selected to the timing of the use of 
levosimendan and the type of intervention. 
 
 
Pharmacology of Levosimendan 
 
Levosimendan is calcium sensitising inodilator 
that binds to troponin C, thereby enhancing 
myofilament responsiveness to calcium. This 
mechanism enhances myocardial contractility, 
maintaining the energy cost of contraction and 
intracellular concentration of calcium at a near normal 
level [1, 13]. Vasodilation is achieved by opening 
adenosine triphosphate (ATP) - sensitive KATP 
channels on smooth muscle cells of systemic and 
coronary vascular bed. Activation of KATP channels 
on cardiac mitochondria explains its cardioprotective 
effects [14]. 
Cardioprotective effects of levosimendan are 
short term (e. g. pre- and postconditioning, anti-
ischemic, anti-stunning), and long term (e.g. anti-
remodeling, anti-inflammatory and anti-apoptotic) [1]. 
Preconditioning refers to the ability of levosimendan to 
protect the heart from ischemia-reperfusion injury by 
preventing calcium overload, saving high energy 
phosphates and stabilising membrane potential due to 
increased potassium influx in cardiac mitochondria 
through activation of KATP channels [1, 14, 15]. 
In animal models, myocardial infarct size was 
significantly decreased after global ischemia- 
reperfusion in both levosimendan pretreatment (45 ± 
2%) and ischemic preconditioning (38 ± 2%) 
compared with controls (52 ± 2%) (p < 0.05). 
Additionally, recent ex-vivo model study of cardiac 
ischemia-reperfusion showed that levosimendan 
pretreatment can decrease the infarct size and 
improve cardiac function [16]. 
The pharmacokinetics of levosimendan 
appears to be similar in patients with heart failure and 
healthy volunteers and remains relatively unaltered by 
gender, age and organ dysfunction [17]. Usually, a 
bolus dose of levosimendan of 6 to 24 µg/kg is used 
followed by continuous infusion of 24 h of 0.05-0.2 
µg/kg in patients with heart failure NYHA classification 
II-IV [15, 18]. After a single dose or intravenous 
infusion, plasma concentration of levosimendan 
increases in a dose-dependent manner [4]. 
Approximately 97-98% is bound to plasma albumins, 
and its plasma half-life is one hour. Levosimendan is 
extensively metabolised through two pathways before 
excretion. The main pathway is conjugation into 
inactive metabolites, while the minor pathway is gut 
reduction into intermediate metabolite (OR-1855) and 
subsequent acetylation into an active metabolite (OR 
1896) [4]. 
The OR-1896 exhibits similar haemodynamic 
influence as levosimendan and a half-life of 
approximately 80 hours [19]. This most likely explains 
the sustained improvements in ventricular 
performance and natriuretic peptide levels compare to 
traditional inotropes [20, 21]. The most often reported 
adverse effect is a headache, observed in 10 % of the 
healthy volunteers receiving levosimendan [4]. Other 
side effects that probably appear due to the 
vasodilatatory effects of levosimendan include 
dizziness, nausea and palpitations. Levosimendan 
acutely reduces systemic vascular resistance and 
ventricular filling pressure. Consequently, in some 
patients with heart failure, it lowers blood pressure 
and vasopressors are required in the first few hours or 
days of administration [22]. 
 
 
Effects of Levosimendan in Patients with 
Heart Failure 
 
Levosimendan has been used in the 
treatment of heart failure (HF) over the past decade. 
Studies have shown clinical improvement in terms of 
hemodynamic parameters, cardiac function, shorter 
overall in-hospital stay, while data for long-term 
mortality is still controversial [23]. 
In a Randomized study of safety and 
effectiveness of Levosimendan in patients with left 
ventricular failure after acute myocardial infarction 
(RUSSLAN), 504 patients were randomised to receive 
either infusion of levosimendan or placebo [24]. 
Patients in levosimendan group experienced reduced 
short-term and long term mortality at 14 days (11.7% 
vs. 19.6%, p = 0.031) and on 180 days (22.6% vs. 
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31.4%, p = 0.053) compared to placebo group [11,24]. 
In the randomised multicenter evaluation of 
intravenous Levosimendan efficacy (REVIVE II) study 
600 patients with acute decompensated heart failure 
(ADFH), were treated with levosimendan (299 
patients) or placebo (301 patients) infusion in addition 
to standard therapy. 58 patients in the levosimendan 
group and only 44 patients in the placebo group got 
improved at 6 h, 24 h and 5 days. By contrast, 82 
patients in the placebo but only 58 patients in the 
levosimendan group got worse (p = 0.015) [10]. In 
respect of mortality at 90 days, there was no 
difference between the groups [25]. 
In SURVIVE study (Survival of patients with 
acute HF in need of intravenous inotropic support), 
which randomised 1327 patient in a double-blind 
fashion to either dobutamine or levosimendan, short-
term (31 days) and long-term (180 days) mortality was 
evaluated in patients with severe ADHF [26]. Patients 
received bolus of levosimendan 12 µg/kg in 10 min, 
followed by 0.1-0.2 µg/kg/min continuous infusion for 
24 h [10]. Mortality rate was evaluated at 5 days, 2 
weeks, 1 and 6 months and the results showed 
reduced mortality for levosimendan group by 27%, 
14%, 13%, and 6.4% respectively, compared to 
dobutamine group, however with no statistically 
significant difference [27]. 
 
 
Levosimendan in Cardiac Surgery 
 
Evidence shows the benefit of coronary 
surgery over medical treatment in patients suffering 
from both decreased left ventricular function and 
coronary artery disease [20, 28]. Patients undergoing 
cardiac surgery with high-risk profile require peri-
operative and post-operative inotropic support and 
levosimedan seems to be an attractive option in such 
patients [23]. Different meta-analyses have suggested 
mortality benefits in patients undergoing cardiac 
surgery receiving levosimendan. Landoni and co-
workers analysed 45 randomised clinical trials 
including 4580 patients and found reduced mortality 
with an OR of 0.35 (95% CI 0.18-0.71, p = 0.003) in 
patients treated with levosimedan [29]. Maharaj and 
co-workers analyzed 17 studies including 729 patients 
after coronary revascularization treated with 
levosimendan versus control, and found mortality 
benefit with an OR of 0.40 (95% confidence interval 
(CI) 0.21 to 0.76, P = 0.005) [28]. 
Harrison and co-workers analysed 14 
randomised controlled trials including 1155 patients, 
evidence showed decreased mortality rate in patients 
intraoperatively treated with levosimendan (risk 
difference −4.2%, 95% CI −7.2% to −1.1%, p = 
0.008), in patients with reduced ejection fraction (EF) 
these benefits were greatest [28]. 
Lim and co-workers analysed 14 studies of 
patients with reduced left ventricular ejection fraction 
(LVEF) undergoing cardiac surgery. Results showed 
reduced early mortality (5.5% vs. 9.1%), reduced 
Intensive care unit stay (ICU) 1.01 (1.61–0.42) days 
and reduced postoperative acute renal injury (ARI) 
(7.4% vs. 11.5%) in patients treated with 
levosimendan [31]. 
Reports from several clinical studies have 
compared levosimendan versus milrinone, placebo, 
dobutamine or intra-aortic balloon pump (IABP)[23]. 
Patients with preserved or reduced left ventricular 
function received levosimendan in pre, intra or post- 
operative setting (period). 
 
 
Pre-Operative Use of Levosimendan in 
Cardiac Surgery 
 
In a trial by Levin and co-workers, 252 high-
risk patients with severely reduced LVEF scheduled 
for coronary artery bypass grafting (CABG), were 
randomized to receive either levosimendan or placebo 
infusion 24 hours pre-operatively. Levosimendan was 
started with a loading dose of 10 µg/kg infusion for 1 h 
than followed by continuous infusion of 0.1 µg/kg/ min 
infusion for 23 h. Reduced mortality was seen in 
levosimendan group compared to placebo (3.9% vs. 
12.8%; P = 0.05), decreased incidence of LCOS 
(7.1% vs. 20.8%; P = 0.05) and complicated weaning 
from CPB (2.4% vs. 9.6%; P = 0.05). In patients 
treated with levosimendan results showed lower 
requirement for other inotropes (7.9% vs. 58.4%; P = 
0.05), vasopressors (14.2% vs. 45.6%; P = 0.05), and 
lower requirements for IABP (6.3% vs. 30.4%; P = 
0.05) compared to placebo group [32]. 
In a randomised, double-blind, placebo-
controlled study by Leppikangas and co-workers, 24 
patients were enrolled and received either 
levosimendan or placebo infusion 24 hours before 
surgery. Results showed improved hemodynamic 
parameters in levosimendan group compared to 
placebo as well as higher levels of levosimendan's 
metabolites compared to other studies that use 
levosimendan in intra-operative setting [33]. 
 
 
Intra-operative Use of Levosimendan 
 
Several trials assessed the effect of 
levosimendan started after induction of anaesthesia or 
before initiation of CPB in patients with preoperatively 
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impaired LVEF. Although the difference in mortality 
rate on patients treated with levosimendan compared 
to placebo or other inotrops showed no statistical 
significance difference, secondary end points such as 
ICU stay, hospital stay, mechanical ventilation, 
requirements for mechanical support and other 
inotrops were significantly decreased [34, 35]. 
In the randomised double-blind trial, Triapepe 
and co-authors compared placebo versus 
levosimendan in 106 patients scheduled for elective 
CABG. Patients receive levosimendan slow i.v. (24 µg 
kg (-1)) or placebo over 10 min before initiation of 
CPB. Results showed significant reduction of the 
length of ICU stay and tracheal intubation time, lower 
level of postoperative troponin I (P < 0.0001) and 
higher cardiac index (P < 0.0001), without a 
statistically significant difference in the study groups in 
respect of 30-day mortality [36]. 
The effect of levosimendan on the 
postoperative outcome with respect to the time of 
administration (early versus late) was assessed in 159 
patients with impaired LVEF less than 35%, in a trial 
conducted by Treskatsh and co-workers. Patients that 
received levosimendan intra-operatively up to the first 
hour after ICU admission showed better survival 
(49/70) compared to patients treated with 
levosimendan infusion after the first hour of ICU 
admission (41/89). The survivors in the late start 
group showed increased incidence of in-hospital 
mortality (p = 0.004) and increased 1-year mortality (p 
= 0.027). Additionally, the incidence of renal 
dysfunction (p = 0.002), requirements for renal 
replacement therapy (RRT) (p = 0.032) and duration 
of mechanical ventilation (p = 0.002) were significantly 
increased in the late start group [37]. 
Järvelä and co-workers randomized 24 
patients with severe aortic stenosis and left ventricular 
hypertrophy scheduled for aortic valve replacement 
(AVR). Levosimendan group received bolus, followed 
by i.v. continuous infusion (0.2 µg/kg/min), and started 
after induction of anaesthesia. LVEF was maintained 
in levosimendan group while it decreased in the 
placebo group, without significant difference [34]. 
Benefits of Levosimendan compared to IABP 
were assessed in a prospective randomised trial of 90 
patients with coronary artery disease and LVEF less 
than 35%, scheduled for surgery [35]. Patients in 
levosimendan group had significantly shorter ICU stay 
compared to other groups (p < 0.01); six hours after 
surgery level of cardiac troponin (cTnI) was increased 
in all groups but significantly lower in the 
levosimendan group. Concentration of cTnI at the first 
postoperative day was 4.67 ng/mL (1.04 to 8.20), 2.40 
ng/mL (1.17 to 5.14), and 2.99 ng/mL (1.52 to 7.40) 
and levels decreased at second post-operative day. 
Furthermore, levosimendan improved hemodynamic 
parameters and contributed to lower cTnI levels 
compared to preoperative IABP [35]. 
Elahi et al. also evaluated the impact of 
preoperative use of either IABP or levosimendan on 
patients outcome, and data showed that in cardiac 
surgery patients with LCOS both improved cardiac 
function, although provided no evidence to suggest 
weather IABP or levosimendan is superior in 
treatment of patients with LCOS with regard to 
morbidity and mortality [38]. 
In a trial by Lahtinen et al. 207 patients 
scheduled for valve ± coronary surgery were 
randomised into placebo or levosimendan group and 
the infusion was initiated after induction of 
anaesthesia. Results showed reduced the number of 
patients with HF in levosimendan group (risk ratio 
0.26, 95% CI0.16-0.43, p = 0.001) but they were more 
likely to require noradrenalin and less likely to require 
IABP compared to placebo group. No significant 
difference in in-hospital and six months mortality 
between the groups [39]. 
 
 
The Use of Levosimandan in Post-
Operative Course 
 
Several studies have evaluated the effect of 
levosimendan on patients with LCOS (defined as CI < 
2.2 l/min/m2, mixed venous saturation < 60%, 
pulmonary wedge pressure > 18 mmHg) after cardiac 
surgery. Levin and colleagues randomised 253 
parents with LCOS after surgery, to receive either 
levosimandan or dobitamine. Patients in 
levosimendan group showed reduced requirements 
for inotrops, vasopressors, IABP use, as well as 
decrease postoperative mortality (7.1 vs. 15.9%) [23, 
40]. 
Alvarez and colleagues randomised 41 
patients after open heart surgery on CPB to either 
levosimendan or dobutamine administered in the 
treatment of post operative LCOS. Although both 
drugs are effective in LCOS treatment, short term 
hemodynamics was improved, levosimendan showed 
significantly greater effects in improving CI (2.9 (0.3) 
l/min/m2 vs. 2.4 (0.2) l/min/m2, p = 0.05) as well as 
significantly reduced systemic and pulmonary 
vascular resistances, also decreased pulmonary 
capillary wedge and central venous pressure(CVP) 
[41]. Al–Shawaf and colleagues conducted a 
randomised trial comparing levosimendan vs 
milrinone for the management of LCOS in diabetic 
patients after cardiac surgery with LVEF < 35%. 
Significantly higher mixed venous saturation, cardiac 
indices, lower pulmonary capillary wedge pressures 
and oxygen extraction rates were found In 
levosimendan group. Therefore, it was suggested that 
levosimendan was more effective in treating 
hemodynamic worsening of post operative LCOS [42]. 
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Treatment of Levosimandan in Patients 
with Right Heart Failure 
 
Several trials have investigated the effects of 
levosimendan on patients with biventricular HF and 
cardiogenic shock related to acute myocardial 
infarction, and demonstrated reduced right ventricle 
(RV) afterload and increased RV contractility [1, 10]. 
Russ and colleagues evaluated the effect of 
levosimandan versus conventional therapy 
(dobutamine and norepinephrine) in patients with 
cardiogenic shock due to myocardial infarction treated 
with percutaneous coronary intervention (PCI). 
Results showed significant increase in cardiac power 
index in both left and right ventricle (2.1 ± 0.1 to 3.0 ± 
0.2, p < 0.01) and (0.14 ± 0.19 to 0.18 ± 0.12, p < 
0.001) respectively, and also decreased pulmonary 
vascular resistance [43]. In a study, Yulmas and 
colleagues randomised 40 patients with significant 
biventricular systolic dysfunction to receive either 
levosimendan or dobutamine and in levosimendan 
group doppler echocardiographic markers of systolic 
function and tricuspid annulus were significantly 
improved (15% ± 12% vs. 2% ± 6%, P < 0.001) versus 
dobutamine [44]. 
 
 
Postoperative Kidney Function in Patients 
Treated with Levosimendan 
 
Postoperative renal dysfunction in patients 
after cardiac surgery is an important complication and 
independently is associated with increased mortality, 
morbidity, prolonged ICU and prolonged overall in-
hospital stay [45]. Several trials have investigated the 
effect of levosimendan in patients with LCOS after 
cardiac surgery the results showed that the drug can 
increase renal blood flow (RBF), CO and by this 
features its reno-protective effects were recognised 
[46, 47]. In one of the latest meta-analysis evaluating 
the renal effect of levosimendan continuous infusion 
0.1 – 0.2 µg/kg/min after loading dose of 6-24 µg/kg 
for 24 h or only loading dose 24 µg/kg in 1h versus 
placebo and/or other inotropic drugs in 13 trials and 
1345 patients, the authors found that levosimendan 
reduces the incidence of postoperative AKI, RRT, 
postoperative mortality, duration of mechanical 
ventilation and ICU stay. In a prospective, double-blind 
clinical trial Baysal and colleagues randomised 128 
patients undergoing mitral valve surgery with LVEF 
less 45 % were to receive either levosimendan 6 
µg/kg/min as a loading dose then 0.1 µg/kg/min after 
aortic clamp removal compared to standard inotropic 
therapy. Patients in the levosimendan group showed 
improved postoperative renal clearance and higher 
values of estimated glomerular filtration rate (eGFR) 
on day 1 and day 3 compared to control group p = 
0.0001, p = 0.0009 respectively and the need of RRT 
was reduced [48]. 
In a retrospective observational study, Balzer 
and colleagues analysed 46 patients with reduced 
LVEF treated with levosimendan as a continuous 
infusion 0.1 µg/kg/min with respect to the timing of it’s 
administration during surgery early versus late start in 
ICU. Intra-operatively 61% of the patients received 
levosimendan versus 39% of patients treated with 
levosimendan in ICU and the results showed 
significantly reduced creatinine plasma levels p= 
0.009, reduced incidence of postoperative renal 
dysfunction (67.9% vs. 94.4%, p = 0.033) and also 
reduced the duration of the RRT [49]. 
Knezevic and al. evaluate the reno-protective 
role of levosimendan versus standard inotropic 
therapy, in 94 patients included for heart 
transplantation. In the first week after transplantation, 
patients in levosimendan group showed increased 
eGFR (62% vs.12%, p = 0.002) with lower incidence 
of AKI (28% vs. 6%, p = 0.01). In the first tree months, 
19% of patients with AKI died versus 8% of patients 
without AKI (p = 0.37). In the study population, the 
one-year survival rate was 87%, without a statistically 
significant difference in mortality rate between the 
groups (11% in levosimandan vs. 15% in control, p = 
0.54)[50]. 
 
 
Cost-Effectiveness of Treatment with 
Levosimendan 
 
Economic and health analysis of treatment 
with levosimendan in acute decompensated heart 
failure showed that it is cost effective. However, in 
cardiac surgery, there is limited data regarding it’s 
cost effective. In an observational study with 292 
patients with acute heart failure, Fedele and 
colleagues preformed cost-effectiveness analysis of 
treatment with levosimendan versus the standard 
treatment with dobutamine. It was found that per 
capita cost of treatment with levosimendan is higher in 
the initial hospitalisation, but when re- hospitalisations 
were considered costs, they were significantly lower 
[23, 51]. Therefore, available data imply that treatment 
with levosimendan in cardiac surgery positively affects 
the elements that are likely to increase the costs of 
treatment: shorter ICU stay, fewer requirements for 
IABP and renal replacement therapy [1]. Furthermore, 
improved indirect indicators may show the advantage 
of levosimendan in cost-effectiveness over 
dobutamine, particularly when administered in high-
risk patients [23]. 
In conclusion, clinical studies show that 
levosimendan enhances the cardiac function and 
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improves the hemodynamic, pulmonary and general 
condition in patients after cardiac surgery in both 
reduced and normal LVEF. Pre operative use of 
levosimendan in high-risk patients with severely 
reduced LVEF may reduce the requirements for 
inotropic support, mechanical support, duration of 
intensive care unit stay as well as hospital stay and 
decrease post operative mortality. The greatest 
benefits may be seen in high-risk patients where 
levosimandan is applied in preoperative setting 24 h 
before surgery. 
 
 
References 
1. Toller W, Heringlake M, Guarracino F , Algotsson L, Alvarez, J, 
Argyriadou H, et al. Preoperative and perioperative use of 
levosimendan in cardiac surgery: European expert opinion. Int J 
Cardiol. 2015;184:323-36. 
http://dx.doi.org/10.1016/j.ijcard.2015.02.022 PMid:25734940 
2. Suleiman MS, Zacharowski K, Angelini G D.Inflammatory 
response and cardioprotection during open-heart surgery: the 
importance of anaesthetics. Br J Pharmacol. 2008;153(1)21-33. 
http://dx.doi.org/10.1038/sj.bjp.0707526 PMid:17952108 
PMCid:PMC2199383 
 
3. Malliotakis P, Xenikakis T, Linardakis M, Hassoulas J. 
Hemodynamic effects of Levosimednan for low cardiac output after 
cardiac surgery: A case series. Hellenic J Cardiol. 2007;48: 80-88. 
PMid:17489345 
 
4. Raja SG, Rayen BS. Levosimendan in cardiac surgery: current 
best available evidence. Ann Thorac Surg. 2006;81(4):1536-46. 
http://dx.doi.org/10.1016/j.athoracsur.2005.08.073 PMid:16564321 
 
5. Amsallem E, Kasparian C, Haddour G, Boissel J P, Nony P. 
Phosphodiesterase III inhibitors for heart failure. Cochrane 
Database of Syst. Rev. 2005; (1): CD002230. 
http://dx.doi.org/10.1002/14651858.cd002230.pub2 
 
6. Overgaard CB, Dzavík V. Inotropes and vasopressors: review of 
physiology and clinical use in cardiovascular disease. Circulation. 
2008;118(10):1047-56. 
http://dx.doi.org/10.1161/CIRCULATIONAHA.107.728840 
PMid:18765387 
 
7. Packer M. The search for the ideal positive inotropic agent. N 
Engl J Med. 1993;329:201–2. 
http://dx.doi.org/10.1056/NEJM199307153290310 PMid:8515793 
 
8. Lee JC, Downing SE. Cyclic AMP and the pathogenesis of 
myocardial injury. Res Commun Chem Pathol Pharmacol. 
1980;27:305–18. PMid:6245436 
 
9. Ferrick KJ, Fein SA, Ferrick AM, et al. Effect of milrinone on 
ventricular arrhythmias in congestive heart failure. Am J Cardiol. 
1990;66:431–4. http://dx.doi.org/10.1016/0002-9149(90)90699-2 
 
10. Nieminen MS, Fruhwald S, Heunks LM, Suominen PK, Gordon 
AC, Kivikko M, et al. Levosimendan: current data, clinical use and 
future development. Heart Lung Vessel. 2013;5:227–245. 
PMid:24364017 PMCid:PMC3868185 
 
11. Antoniades C, Tousoulis D, Koumallos N, Marinou K, 
Stefanadis C. Levosimendan: beyond its simple inotropic effect in 
heart failure. Pharmacol Ther. 2007;114(2):184-97. 
http://dx.doi.org/10.1016/j.pharmthera.2007.01.008 PMid:17363065 
 
12. Caimmi PP, Kapetanakis EI, Beggino C, Molinari C, Giustini G, 
Crosio E, et al. Management of acute cardiac failure by 
intracoronary administration of levosimendan. J Cardiovasc 
Pharmacol. 2011;58:246–53. 
http://dx.doi.org/10.1097/FJC.0b013e318220e491 PMid:21654504 
 
13. Kamath SR, Jaykumar I, Matha S. Levosimendan. Indian 
Pediatr. 2009;46:593–596. PMid:19638658  
14. Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F. 
Pharmacology of levosimendan: inotropic, vasodilatory and 
cardioprotective effects. J Clin Pharm Ther. 2013;38(5):341-9. 
http://dx.doi.org/10.1111/jcpt.12067 PMid:23594161 
 
15. Kasikcioglu HA, Cam N. A review of levosimendan in the 
treatment of heart failure. Vasc Health Risk Manag. 2006;2(4):389-
400. http://dx.doi.org/10.2147/vhrm.2006.2.4.389 
 
16. Lepran I, Pollesello P, Vajda S, Varró A, Papp G J. 
Preconditioning effects of levosimendan in a rabbit cardiac 
ischemia–reperfusion model. J. Cardiovasc. Pharmacol. 
2006;48:148–152. 
http://dx.doi.org/10.1097/01.fjc.0000246151.39758.2a 
PMid:17086092 
 
17. Ng TM. Levosimendan, a new calcium-sensitizing inotrope for 
heart failure. Pharmacotherapy. 2004;24:1366–84. 
http://dx.doi.org/10.1592/phco.24.14.1366.43145 
 
18. Jonsson N E, Antila S, McFadyen L, Lehtonen L, Karlsson M. 
Population pharmacokinetics of levosimendan in patients with 
congestive heart failure. Br J Clin Pharmacy. 2003;55(6):544-551. 
http://dx.doi.org/10.1046/j.1365-2125.2003.01778.x 
PMCid:PMC1884248 
 
19. Moreno N, Tavares-Silva M, Lourenço AP, Pinto J O, 
Henriques-Coelho T, Leite-Moreira AF. Levosimendan: The current 
situation and new prospects. Rev Port Cardiol. 2014;33(12):795-
800. http://dx.doi.org/10.1016/j.repc.2014.05.009 PMid:25459636 
 
20. Eriksson HI, Jalonen JR, Heikkinen LO, Kivikko M, Laine M, 
Leino KA, et al. Levosimendan facilitates weaning from 
cardiopulmonary bypass in patients undergoing coronary artery 
bypass grafting with impaired left ventricular function. Ann Thorac 
Sure. 2009;87:448–454. 
http://dx.doi.org/10.1016/j.athoracsur.2008.10.029 PMid:19161758 
 
21. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic 
effects of intravenous levosimendan. Circulation. 2003;107:81–6. 
http://dx.doi.org/10.1161/01.CIR.0000043245.00859.11 
PMid:12515747 
 
22. Nieminen MS, Buerke M, Cohen-Solál A, Costa S, Édes I, 
Erlikh A, Franco F, et al. The role of levosimendan in acute heart 
failure complicating acute coronary syndrome: A review and expert 
consensus opinion. Int J Cardiol. 2016;218:150-157. 
http://dx.doi.org/10.1016/j.ijcard.2016.05.009 PMid:27232927 
 
23. Shi WY, Li S, Collins N, Cotten DB, Bastian BC, James AN, 
Mejia R. Peri- operative Levosimendan in Patients Undergoing 
Cardiac Surgery: An Overview of the Evidence. Heart Lung Circ. 
2015;24(7):667-72. http://dx.doi.org/10.1016/j.hlc.2015.03.007 
PMid:25862519 
 
24. De Luca L, Colucci WS, Nieminen MS, Massie BM, 
Gheorghiade M. Evidence-based use of levosimendan in different 
clinical settings. Eur Heart J. 2006;27:1908-20. 
http://dx.doi.org/10.1093/eurheartj/ehi875 PMid:16682381 
 
25. Delaney A, Bradford, C, McCaffrey J, Bagshaw S M, Lee R. 
Levosimendan for the treatment of acute severe heart failure: A 
meta-analysis of randomised controlled trials. Int J Cardiol. 
2010;138(3):281-9. http://dx.doi.org/10.1016/j.ijcard.2008.08.020 
PMid:18817994 
 
26. Mebazaa A, Nieminen MS, Filippatos G S, Cleland JG, Salon 
JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A. 
Levosimendan vs. dobutamine: outcomes for acute heart failure 
patients on beta-blockers in SURVIVE. Eur J Heart Fail. 
2009;11:304–311. http://dx.doi.org/10.1093/eurjhf/hfn045 
PMid:19158152 PMCid:PMC2645051 
 
27. Cohen-Solal A, Logeart D, Huang B, et al.Lowered B type 
natriuretic peptide in response to levosi mendan or dobutamine 
treatment is associated with improved survival in patients with 
severe acutely decompensated heart failure. J Am Coll Cardiol. 
2009;53:23432348. http://dx.doi.org/10.1016/j.jacc.2009.02.058 
PMid:19539144 
 
28. Harrison R W, Hasselblad V, Mehta R H, Levin R, Harrington 
RA, Alexander JH. Effect of levosimendan on survival and adverse 
events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc 
Anesth. 2013;27:1224–32. 
 
Review Article 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  516                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
http://dx.doi.org/10.1053/j.jvca.2013.03.027 PMid:24050857 
29. Landoni G, Mizzi A, Biondi-Zoccai G, et al., Reducing mortality 
in cardiac surgery with levosimendan: a meta-analysis of 
randomized controlled trials. J Cardiothorac Vasc Anesth. 
2010;24:51–57. http://dx.doi.org/10.1053/j.jvca.2009.05.031 
PMid:19700350 
 
30. Maharaj R, Metaxa V. Levosimendan and mortality after 
coronary revascularisation: a meta-analysis of randomised 
controlled trials. Crit Care. 2011;15:R140. 
http://dx.doi.org/10.1186/cc10263 PMid:21651806 
PMCid:PMC3219012 
 
31. Lim JY , Deo SV, Rababa'h A, Altarabsheh SE, Cho YH, Hang 
D, et al. Levosimendan reduces mortality in adults with left 
ventricular dysfunction undergoing cardiac surgery: a systematic 
review and meta-analysis. J Card Surg. 2015;30:547–554. 
http://dx.doi.org/10.1111/jocs.12562 PMid:25989324 
 
32. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. 
Preoperative levosimendan decreases mortality and the 
development of low cardiac output in high-risk patients with severe 
left ventricular dysfunction undergoing coronary artery bypass 
grafting with cardiopulmonary bypass. Exp Clin Cardiol. 
2012;17:125–30. PMid:23620700 PMCid:PMC3628425 
 
33. Leppikangas H, Järvelä K, Sisto T, Maaranen P, Virtanen M, 
Lehto P, et al. Preoperative levosimendan infusion in combined 
aortic valve and coro- nary bypass surgery. Br J Anaesth. 
2011;106:298–304. http://dx.doi.org/10.1093/bja/aeq402 
PMid:21258075 
 
34. Järvelä K, Maaranen P, Sisto T, Ruokonen E. Levosimendan in 
aortic valve surgery: car- diac performance and recovery. J 
Cardiothorac Vasc Anesth. 2008;22:693–698. 
http://dx.doi.org/10.1053/j.jvca.2008.01.024 PMid:18922425 
 
35. Lomivorotov VV, Boboshko VA, Efremov SM, et al. 
Levosimendan versus an intra-aortic balloon pump in high-risk 
cardiac patients. J Cardiothorac Vasc Anesth. 2012;26:596–603. 
http://dx.doi.org/10.1053/j.jvca.2011.09.006 PMid:22051419 
 
36. Tritapepe L, De Santis V, Vitale D, Guarracino F, Pellegrini F, 
Pietropaoli P, et al. Levosimendan pre-treatment improves 
outcomes in patients undergoing coronary artery bypass graft 
surgery. Br J Anaesth. 2009;102: 198–204. 
http://dx.doi.org/10.1093/bja/aen367 PMid:19151048 
 
37. Treskatsch S, Balzer F, Geyer T, Spies CD, Kastrup M, 
Grubitzsch H, et al. Early levosimendan administration is 
associated with decreased mortality after cardiac surgery. J Crit 
Care. 2015;30(4):859.e1-6. 
http://dx.doi.org/10.1016/j.jcrc.2015.03.008 PMid:25837801 
 
38. Elahi MM, Lam J, Asopa S, Matata BM. Levosimendan versus 
an intra-aortic balloon pump in adult cardiac surgery patients with 
low cardiac output. J Cardiothorac Vasc Anesth. 2011; 25(6):1154–
62. http://dx.doi.org/10.1053/j.jvca.2011.01.001 PMid:21376634 
 
39. Lahtinen P, Pitkänen O, Pölönen P, et al. Levosimendan 
reduces heart failure after cardiac surgery – a prospective, 
randomized, placebocontrolled trial. Crit Care Med. 2011;39:2263-
2270. http://dx.doi.org/10.1097/CCM.0b013e3182227b97 
PMid:21666445 
 
40. Levin R, Porcile R, Salvagio F, Del Mazo C, Botbol A, Tanus E, 
et al. Levosimendan reduces mortality in post-operative low cardiac 
output syndrome after coronary surgery. Circulation. 
2009;120:S987–8. 
 
41. Alvarez J, Bouzada M, Fernández AL, et al. Hemodynamic 
effects of levosimendan compared with dobutamine in patients with 
low cardiac output after cardiac surgery. Rev Esp Cardiol. (Engl. 
Ed.). 2006;59:338–345. http://dx.doi.org/10.1016/S1885-
5857(06)60770-6 
 
42. Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi 
R. Levosimendan or milrinone in the type 2 diabetic patient with 
low ejection fraction undergoing elective coronary artery surgery. J 
Cardiothorac Vasc Anesth. 2006;20:353–357. 
http://dx.doi.org/10.1053/j.jvca.2006.02.012 PMid:16750735 
 
43. Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, 
 
Schmidt H, Lemm H. et al. Right ventricular function in myocardial 
infarction complicated by cardiogenic shock: Improvement with 
levosimendan. Crit Care Med. 2009;37(12):3017–3023. 
http://dx.doi.org/10.1097/CCM.0b013e3181b0314a PMid:19661807 
44. Yilmaz M B, Yontar C, Erdem A, Karadas F, Yalta K, Turgut O, 
et al. Comparative effects of levosimendan and dobutamine on 
right ventricular function in patients with biventricular heart failure. 
Heart Vessels. 2009;24(1):16–21. 
http://dx.doi.org/10.1007/s00380-008-1077-2 PMid:19165563 
 
45. Niu ZZ, Wu SM, Sun WY, Hou WM, & Chi YF. Perioperative 
levosimendan therapy is associated with a lower incidence of acute 
kidney injury after cardiac surgery: a meta- analysis. J Cardiovasc 
Pharmacol. 2014;63(2):107-12. 
http://dx.doi.org/10.1097/FJC.0000000000000028 PMid:24126568 
 
46. Zorlu A, Yucel H, Yontar OC, Karahan O, Tandogan I, 
Katrancioglu N, et al. Effect of levosimendan in patients with 
severe systolic heart failure and worsening renal function. Arq Bras 
Cardiol. 2012;98:537–43. http://dx.doi.org/10.1590/S0066-
782X2012005000048 PMid:22641390 
 
47. Zhou C, Gong J, Chen D, Wang W, Liu M, Liu B. 
Levosimendan for prevention of acute kidney injury after cardiac 
surgery: A Meta-analysis of controlled trials. Am J Kidney Dis. 
2016;67(3):408-16. http://dx.doi.org/10.1053/j.ajkd.2015.09.015 
PMid:26518388 
 
48. Baysal A, Yanartas M, Dogukan M , Gundogus N , Kocak T, 
Koksal C. Levosimendan improves renal outcome in cardiac 
surgery: a randomised trial. J Cardiothorac Vasc Anesth. 
2014;28:586–594. http://dx.doi.org/10.1053/j.jvca.2013.09.004 
PMid:24447501 
 
49. Balzer F, Treskatsch S, Spies C, Sander M, Kastrup M, 
Grubitzsch H, et al. Early administration of levosimendan is 
associated with improved kidney function after cardiac surgery, a 
retrospective analysis. J Cardiothorac Surg. 2014;9:167. 
http://dx.doi.org/10.1186/s13019-014-0167-8 PMid:25399779 
PMCid:PMC4240807 
 
50. Knezevic I, Poglajen G, Hrovat E, Oman A, Pintar T, et al. The 
effects of levosimendan on renal function early after heart 
transplantation: results from a pilot randomized trial. Clin 
Transplant. 2014;28(10):1105-11. 
http://dx.doi.org/10.1111/ctr.12424 PMid:25053182 
 
51. Fedele F, et al. Cost-effectiveness of levosimendan in patients 
with acute heart failure. J Cardiovasc Pharmacol. 2011; 58(4):363-
6. http://dx.doi.org/10.1097/FJC.0b013e318224e0a2 
PMid:21697728 
 
 
